SLE patients with active cutaneous lupus erythematosus (CLE) treated with anti-BDCA2 antibody litifilimab (also known as BIIB059) showed an approximately 50% reduction in IFNGS expression in whole blood 24 hours after treatment, and litifilimab treatment was highly effective in normalizing IFN response proteins (myxovirus resistance protein 1 and IFN-induced transmembrane protein 3) in lesional skin and reducing CD45+ immune cell infiltration (52). This evidence concerns the gene CLEC4C and systemic lupus erythematosus.